KEI and UACT Comments to NIH on Proposed Exclusive License to Connectyx

On Friday September 11, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Anti-CD56 as an Antibody-Drug Conjugate… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License to ONK Therapeutics

(Update: The NIH has provided a response to our comments on August 31, 2020) On August 28, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) “Prospective… Continue Reading

KEI Comments Regarding NIH Exclusive License to PreciThera

(Update: The NIH provided a response to our comments on August 24, 2020) On August 20, 2020, Knowledge Ecology International (KEI) submitted comments regarding the prospective grant of an exclusive license by the National Institutes of Health (NIH) to PreciThera,… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License to Cytovia for CAR Technology

On August 14, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the NIH’s “Prospective Grant of an Exclusive Patent License: Allogeneic Therapy Using Chimeric Antigen Receptors Targeting GPC3” (85 FR 45912). The… Continue Reading

KEI Comments Regarding NIH Exclusive License to RNAceuticals for Anti-HIV Antibodies

On July 27, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent Commercialization License: N6, a Novel, Broad, Highly Potent HIV-Specific Antibody and a Broadly Neutralizing Human Anti-HIV… Continue Reading

KEI Comments Regarding NIH Exclusive License to Paz Pharmaceuticals for Cancer Treatment

On July 7, 2020, Knowledge Ecology International (KEI) submitted comments to the Federal Register notice for the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fenoterol and Certain Fenoterol Analogues for the… Continue Reading

KEI Comments Regarding NIH Exclusive License to TeraImmune for T Cell Therapy

(UPDATE: The NIH provided a response to our comments on February 25, 2020) On February 3, 2020, Knowledge Ecology International (KEI) submitted comments to the “Prospective Grant of Exclusive Patent License: Development of Regulatory T-Cell Therapies for the Treatment of… Continue Reading